XGNNasdaqServices-Medical LaboratoriesFiscal year ends December 31

EXAGEN INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$7.43−0.29 (-3.76%)

Close on Oct 19, 2026

Market cap: $179.54M
P/E (TTM): –
Dividend yield: –

EXAGEN INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Revenue	67	56	53	46	48	42	40	32
Cost of Revenue	28	23	23	24	21	17	19	15
Gross Profit	39	33	29	21	28	25	22	17
Research & Development	6.25	5.38	4.87	9.88	7.24	3.57	2.18	2.13
Selling, General & Admin	47	41	47	52	45	37	29	20
Advertising Expenses	1.70	1.40	1.50	3.00	1.70	1.30	1.60	1.40
Total Costs & Expenses	53	47	52	92	72	57	50	37
Operating Income	-14	-14	-23	-46	-24	-15	-9.30	-4.88
Interest Expense	4.32	2.23	2.34	2.45	2.63	2.57	3.49	2.87
Interest & Investment Income	0.29	0.77	1.52	–	–	–	–	–
Other Non-Operating Income	–	–	–	–	0.02	0.98	0.51	0.11
Asset Impairment Charges	–	–	0	5.51	0	–	–	–
Gain (Loss) on Sale of Assets	–	-0.11	-0.19	0	–	0	-0.02	-0.01
Income Tax Expense	0.05	0.01	0.03	-0.28	0.18	-0.08	0.03	0.06
Net Income	-20	-15	-24	-47	-27	-17	-12	-8.01
Net Income to Common	–	–	–	–	–	-17	-30	-18
EPS (Basic)(per share)	-0.93	-0.83	-1.34	-2.77	-1.68	-1.32	-8.46	-293.34
EPS (Diluted)(per share)	-0.93	-0.83	-1.34	-2.77	-1.68	-1.32	-8.46	-293.34
Shares Outstanding (Basic, Weighted)(shares)	22	18	18	17	16	13	3.58	0.06
Shares Outstanding (Diluted, Weighted)(shares)	22	18	18	17	16	13	3.58	0.06
EBITDA	-12	-12	-21	-44	-23	-15	-8.70	-4.28

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 58.6%
Operating margin: -18.6%
Net margin: -26.6%
Return on equity, FY2025: -147.8%

Financial strength

Current ratio: 3.18
Debt to equity: 1.87
Debt to assets: 44.0%
Cash to current liabilities: 182.7%

Valuation

P/E ratio: –
Price to sales: 2.52
Price to book: 14.70
Dividend yield: –